| News

Novaremed secures US$50 million

03.02.2021

Basel biotech Novaremed is receiving US$50 million through an agreement with an investment group. Novaremed will use this financing to progress the clinical development of its treatment for painful diabetic peripheral neuropathy.

The Luxembourg-based investment group GEM Global Yield has committed to provide Novaremed with up to US$50 million over a 36-month term. In return, GEM will have the right to purchase shares of Novaremed following the public listing of the company, as was explained in a press release from the Basel biotech. Novaremed will control the timing and maximum amount of drawdown under this share subscription facility.

“This funding agreement with GEM will help us, upon the company’s public listing, to advance our highly innovative lead product that we are developing for the non-opioid treatment of patients affected by diabetes-related chronic neuropathic pain,” said Isaac Kobrin, Executive Chairman of the Board of Novaremed, in the press release. His company was founded in Israel in 2008 and set up in Basel at the end of 2017. Basel Area Business & Innovation, the investment and innovation promotion agency, supported Novaremed in making the move.

Novaremed’s lead product, NRD135S.E1, is an investigational non-opioid small molecule drug for the treatment of painful diabetic peripheral neuropathy. Patients suffering from this experience a painful burning or tingling sensation in areas such as the hands or feet and lower legs. This debilitating neuropathic pain substantially impairs quality of life. Given the ongoing opioid crisis with addiction to pain medication a growing problem, the non-opioid drug developed by Novaremed is a novel alternative treatment.

GEM’s investment represents the largest funding round for a Swiss startup this January, as was reported in a press release on the Startup.ch platform about the latest Swiss Venture Capital Report. Startups from the Basel Area also received the most financing of all regions.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Roche tests able to detect Omicron
Basel Area Business & Innovation, Innovation, Invest

Roche tests able to detect Omicron

The Roche subsidiary TIB Molbiol has developed new coronavirus testing kits that can also detect the new Omicron variant of...

Read More
Hemex banks 7.1 million Swiss francs
Basel Area Business & Innovation, Innovation, Invest

Hemex banks 7.1 million Swiss francs

Hemex has raised a total of 7.1 million Swiss francs as part of a Series C financing round. The company...

Read More
EsoCap impresses investors
Basel Area Business & Innovation, Innovation, Invest

EsoCap impresses investors

EsoCap, a biotech company based in Basel, has concluded a successful funding round. The funds from new and existing investors...

Read More
Plug and Play settles in the Basel Area
Basel Area Business & Innovation, Innovation, Invest

Plug and Play settles in the Basel Area

Plug and Play is coming to the canton of Basel-Landschaft. The first founding partner of the innovation promoter from Silicon...

Read More
Bachem builds its largest production building
Basel Area Business & Innovation, Innovation, Invest

Bachem builds its largest production building

Bachem has laid the foundation stone for its largest production building to date. The company specializing in the manufacture of...

Read More
Bottneuro advancing personalized Alzheimer’s therapy
Basel Area Business & Innovation, Innovation, Invest

Bottneuro advancing personalized Alzheimer’s therapy

Basel-based startup Bottneuro is working on the development of personalized therapies to treat Alzheimer’s disease in which certain areas of...

Read More
1 2 3 50

Do you have a question? We'd like to hear from you.